Stool-based SDC2 DNA Methylation Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

NCT04221854 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50000

Last updated 2020-02-18

No results posted yet for this study

Summary

The primary objective is to compare the performance of Stool-based SDC2 DNA Methylation Test and commercially available Fecal Immunochemical Test(FIT) , on the detection rate of advanced adenomatous polyps and colorectal cancer in Chinese population. Subjects with positive results in either test will receive colonoscopy. Lesions will be confirmed as malignant or precancerous by colonoscopy and histopathologic examination.

Conditions

Interventions

DIAGNOSTIC_TEST

Stool-based SDC2 DNA methylation test

Stool-based SDC2 DNA methylation test

DIAGNOSTIC_TEST

Fecal immunochemical test

Fecal immunochemical test

Sponsors & Collaborators

  • Shanghai Municipal Center for Disease Control and Prevention

    collaborator OTHER
  • Changhai Hospital

    collaborator OTHER
  • Tianjin Nankai Hospital

    collaborator OTHER
  • Peking University People's Hospital

    collaborator OTHER
  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    collaborator OTHER
  • Guangzhou Center for Disease Control and Prevention

    collaborator OTHER_GOV
  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Kai Gu, MD · Shanghai Municipal Center for Disease Control and Prevention

  • Enda Yu, MBBS · Changhai Hospital

  • Ximo Wang, MD, PhD · Tianjin Nankai Hospital

  • Shan Wang, MD, PhD · Peking University People's Hospital

  • Jiahua Leng, MD, PhD · Peking University Cancer Hospital & Institute

  • Dong Xu, MD, PhD · Second Affiliated Hospital, School of Medicine, Zhejiang University

  • Pengzhe Qin, MD · Guangzhou Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04221854 on ClinicalTrials.gov